FDA drafts pharma exec prosecution guidelines

The FDA has drafted guidelines for selecting the cases in which it will pursue misdemeanor prosecutions of corporate officers, holding them accountable for lingering GMP breaches and other violations of the Food, Drug and Cosmetics Act. The guidelines are being reviewed internally, reports law firm Bryan Cave, and the regulator expects to make public the final version. Item 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.